Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients

Oster, Howard S.; Prutchi-Sagiv, Sara; Halutz, Ora; Shabtai, Esther; Hoffman, Michael A.; Neumann, Drorit; Mittelman, Moshe

doi:10.1016/j.exphem.2012.10.011

Cited by 11 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, we 29 , 54 – 56 , 58 , 60 and others 61 , 62 have linked EPO administration to prolonged survival and improved immunological functions in multiple myeloma (MM) mouse models and MM patients. Moreover, EPO treatment in hematologic patients improved the response to influenza vaccination 63 and normalized the levels of impaired CD4 + and CD8 + T cell and CD4 + CD25 + cell numbers in low risk myelodysplastic syndrome patients (MDS) 64 .…”

Section: Discussionmentioning

confidence: 99%

Erythropoietin enhances Kupffer cell number and activity in the challenged liver

Gilboa

Haim-Ohana

Deshet-Unger

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Erythropoietin (EPO) is the main hormone driving mammalian erythropoiesis, with activity mediated via the surface receptor, EPO-R, on erythroid progenitor cells. Recombinant human EPO is currently used clinically for the treatment of anemia in patients with end-stage renal disease, and in certain cancer patients suffering from anemia induced either by the tumor itself or by chemotherapy. EPO-R expression is also detected in non-erythroid cells, including macrophages present in the peritoneum, spleen, and bone marrow (BM). Here we demonstrate that Kupffer cells (KCs) - the liver-resident macrophages - are EPO targets. We show that, in vitro, EPO initiated intracellular signalling and enhanced phagocytosis in a rat KC line (RKC-2) and in sorted KCs. Moreover, continuous EPO administration in mice, resulted in an increased number of KCs, up-regulation of liver EPO-R expression and elevated production of the monocyte chemoattractant CCL2, with corresponding egress of Ly6Chi monocytes from the BM. In a model of acute acetaminophen-induced liver injury, EPO administration increased the recruitment of Ly6Chi monocytes and neutrophils to the liver. Taken together, our results reveal a new role for EPO in stimulating KC proliferation and phagocytosis, and in recruiting Ly6Chi monocytes in response to liver injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Erythropoietin enhances Kupffer cell number and activity in the challenged liver

Gilboa

Haim-Ohana

Deshet-Unger

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar results were found in an experimental study using mice, which showed that EPO-treated mice had an enhanced immune response to the clinically-relevant HBV surface Ag (62). Oster et al also reported that EPO treatment is associated with an improved immune response to influenza vaccine in hematologic patients, with titers similar to those of healthy subjects, although they did not examine the renal function of the patients (63). However, a meta-analysis of 11 studies failed to detect any benefit of EPO treatment regarding the response to HBV vaccine (64).…”

Section: Modulation Of DC Function In Patients With Esrdmentioning

confidence: 99%

Dendritic Cell Dysfunction in Patients with End-stage Renal Disease

Kim

et al. 2017

Immune Netw

View full text Add to dashboard Cite

End-stage renal disease (ESRD) with immune disorder involves complex interactions between the innate and adaptive immune responses. ESRD is associated with various alterations in immune function such as a reduction in polymorphonuclear leukocyte bactericidal activity, a suppression of lymphocyte proliferative response to stimuli, and a malfunction of cell-mediated immunity at the molecular level. ESRD also increases patients' propensity for infections and malignancies as well as causing a diminished response to vaccination. Several factors influence the immunodeficiency in patients with ESRD, including uremic toxins, malnutrition, chronic inflammation, and the therapeutic dialysis modality. The alteration of T-cell function in ESRD has been considered to be a major factor underlying the impaired adaptive cellular immunity in these patients. However, cumulative evidence has suggested that the immune defect in ESRD can be caused by an Ag-presenting dendritic cell (DC) dysfunction in addition to a T-cell defect. It has been reported that ESRD has a deleterious effect on DCs both in terms of their number and function, although the precise mechanism by which DC function becomes altered in these patients is unclear. In this review, we discuss the effects of ESRD on the number and function of DCs and propose a possible molecular mechanism for DC dysfunction. We also address therapeutic approaches to improve immune function by optimally activating DCs in patients with ESRD.

show abstract

“…These observations suggest an important role for Epo in regulating adaptive immune responses. Indeed, Epo has been demonstrated to up-regulate antibody (Ab) production [5], facilitate the generation of antigen-specific CD8 + cytotoxic T cells (CTLs) and sustain functional activity of CD4 + Т-helper (Th) cells in patients with chronic renal failure undergoing hemodialysis treatment [6]. Epo-mediated effects are considered to be associated with the up-regulation of dendritic cell differentiation activity and the enhancement of their antigen presentation capacity [4], as well as with the direct anti-apoptotic impact of Epo on T-cells [7] and the stimulation of T-cell-dependent IL-2 production [8].…”

Section: Introductionmentioning

confidence: 99%

Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes

Тодосенко

Shmarov

Малащенко

et al. 2016

International Immunopharmacology

View full text Add to dashboard Cite

Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients

Cited by 11 publications

References 28 publications

Erythropoietin enhances Kupffer cell number and activity in the challenged liver

Erythropoietin enhances Kupffer cell number and activity in the challenged liver

Dendritic Cell Dysfunction in Patients with End-stage Renal Disease

Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes

Contact Info

Product

Resources

About